Pfizer Drops $118 Billion AstraZeneca Bid As Time Runs Out

Law360, New York (May 26, 2014, 11:37 AM EDT) -- Pfizer Inc. said Monday it will no longer pursue its sweetened £69.4 billion ($118 billion) offer for rival drug maker AstraZeneca plc, which kept up its stiff opposition to the bid even as it ran up against the end of the deadline period mandated by U.K. takeover rules.

The deal's chances had been growing slimmer as Monday's deadline approached. AstraZeneca kept up its opposition, saying the deal undervalued it, even as some of its biggest investors lobbied for negotiations.

AstraZeneca executives had said Pfizer would need to raise its offer more than 10 percent to win over the board. Takeover rules prevent the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!